ESR1 and breast carcinoma: However, whether ER+ breast cancer patient with CCNA2 overexpression could benefit from the repression of CCNA2, or in other words, whether CCNA2 is a promising target for preventing or could reverse tamoxifen resistance still needs more experimental support.